肺炎支原体耐药机制研究进展  

Research progress in mechanism of drug resistance of Mycoplasma pneumoniae

作　　者：过毅[1] 葛小丽[1] 吴莹莹[1] 周晓飞[1] 

机构地区：[1]无锡市第二人民医院儿科,江苏无锡214002

出　　处：《中华医院感染学杂志》2016年第20期4782-4784,共3页Chinese Journal of Nosocomiology

基　　金：江苏省科技厅基金资助项目(BL2014023)

摘　　要：肺炎支原体(MP)是社区获得性及医院获得性感染常见病原体,大环内酯类抗菌药物为治疗儿童MP感染首选药物,但国内大环内酯类耐药情况严重,探讨MP耐药机制有重要的临床意义;简述了目前MP耐药现状,介绍了近年来耐药机制的研究进展,指出了耐药机制主要为23SrRNA中V区基因及L4、L22蛋白突变,是否存在新的耐药机制仍在研究中;耐药机制的研究将为抗菌药物改造、疫苗、靶向药物的研发提供理论基础,提出了临床医师应重视MP高耐药性的严峻形势,规范使用抗菌药物,同时应完善MP耐药性的监测和管理。Macrolides antibiotics are the first choice for children infected by Mycoplasma pneumoniae （MP） which is a common pathogen of community acquired infections,as well as hospital acquired infections. Drug resistance of MP is quite severe in China, it has an important clinical significance to investigate the drug resistance mechanism of MP. This review summarized the current status of drug resistance of MP,and introduced the research progress of drug resistance mechanism in recent years. The key mechanism of drug resistance was thought to be mutations of genes located in domain V of 23SrRNA and protein L4 and L22. Relevant researches also focused on new mech- anisms. Studies of drug resistance mechanisms will provide theoretical basis for the development of antibiotics, vaccines and targeted drugs. Clinicians should pay attention to the severe drug resistance of MP and use antibiotics properly. Meanwhile,the monitoring and management of MP drug resistance should be improved.

关 键 词：肺炎支原体 大环内酯类耐药 耐药机制 基因突变 

分 类 号：R375.2[医药卫生—病原生物学]